Insight into the dichotomous regulation of STING activation in immunotherapy

References

• Shekarian T, Valsesia-Wittmann S, Caux C, et al. Paradigm shift in oncology: targeting the immune system rather than cancer cells. Mutagenesis. 2015;30(2):205–211.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of Pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. EMBO J. 1992;11(11):3887–3895.
   PubMed Web of Science ®Google Scholar
• Yu S, Li A, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.
   PubMed Web of Science ®Google Scholar
• Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–1379.
   PubMed Web of Science ®Google Scholar
• Ma S, Li XC, Wang XY, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–2560.
   PubMed Web of Science ®Google Scholar
• Stern LA, Jonsson VD, Priceman SJ. CAR T cell therapy progress and challenges for solid tumors. Cancer Treat Res. 2020;180:297–326.
   PubMedGoogle Scholar
• Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830–842.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–852.
   PubMed Web of Science ®Google Scholar
• Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018–1030.
   PubMed Web of Science ®Google Scholar
• Ahn J, Xia TL, Konno H, et al. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun. 2014;5:5166.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;456(7219):274–274.
   Web of Science ®Google Scholar
• Corrales L, McWhirter SM, Dubensky TW, et al. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126(7):2404–2411.
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Pattern recognition theory and the launch of modern innate immunity. J Immunol. 2013;191(9):4473–4474.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305.
   PubMed Web of Science ®Google Scholar
• Morehouse BR, Govande AA, Millman A, et al. STING cyclic dinucleotide sensing originated in bacteria. Nature. 2020;586(7829):429–433.
   PubMed Web of Science ®Google Scholar
• Luthra P, Aguirre S, Yen BC, et al. Topoisomerase II inhibitors induce DNA damage-dependent interferon responses circumventing Ebola virus immune evasion. mBio. 2017;8(2):e00368-17.
   PubMed Web of Science ®Google Scholar
• Gao P, Ascano M, Wu Y, et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell. 2013;153(5):1094–1107.
   PubMed Web of Science ®Google Scholar
• Zhao B, Du F, Xu P, et al. A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1. Nature. 2019;569(7758):718–722.
   PubMed Web of Science ®Google Scholar
• Khoo LT, Chen LY. Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches. EMBO Rep. 2018;19(12):e46935.
   PubMed Web of Science ®Google Scholar
• Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760–770.
   PubMed Web of Science ®Google Scholar
• Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS–STING signalling. Nat Rev Mol Cell Biol. 2020;21(9):501–521.
   PubMed Web of Science ®Google Scholar
• Vatner RE, Janssen EM. STING, DCs and the link between innate and adaptive tumor immunity. Mol Immunol. 2019;110:13–23.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev. 2010;234(1):5–17.
   PubMedGoogle Scholar
• Wang H, Hu S, Chen X, et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc Natl Acad Sci U S A. 2017;114(7):1637–1642.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Woo SR, Burnett B, et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34(2):67–73.
   PubMed Web of Science ®Google Scholar
• Liu HP, Zhang HP, Wu XY, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. Nature. 2018;563(7729):131–136.
   PubMed Web of Science ®Google Scholar
• Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64(3):358–367.
   PubMed Web of Science ®Google Scholar
• Curran E, Chen X, Corrales L, et al. STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell Rep. 2016;15(11):2357–2366.
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249–253.
   PubMed Web of Science ®Google Scholar
• Padovan E, Spagnoli GC, Ferrantini M, et al. IFN-alpha 2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8(+) effector T cells. J Leukoc Biol. 2002;71(4):669–676.
   PubMed Web of Science ®Google Scholar
• Lv MZ, Chen MX, Zhang R, et al. Manganese is critical for antitumor immune responses via cGAS–STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30(11):966–979.
   PubMed Web of Science ®Google Scholar
• Sze A, Belgnaoui SM, Olagnier D, et al. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe. 2013;14(4):422–434.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Marques JT, Yamashita M, et al. Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J. 2010;29(10):1762–1773.
   PubMed Web of Science ®Google Scholar
• Foote JB, Kok M, Leatherman JM, et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. Cancer Immunol Res. 2017;5(6):468–479.
   PubMed Web of Science ®Google Scholar
• White MJ, McArthur K, Metcalf D, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell. 2014;159(7):1549–1562.
   PubMed Web of Science ®Google Scholar
• Tang C-HA, Zundell JA, Ranatunga S, et al. Agonist-mediated activation of STING induces apoptosis in malignant B cells. Cancer Res. 2016;76(8):2137–2152.
   PubMed Web of Science ®Google Scholar
• Gui X, Yang H, Li T, et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature. 2019;567(7747):262–266.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Hu H, Liu H, et al. A synthetic STING agonist inhibits the replication of human parainfluenza virus 3 and rhinovirus 16 through distinct mechanisms. Antiviral Res. 2020;183:104933.
   PubMed Web of Science ®Google Scholar
• Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS–STING pathway in cancer. Cancer Discov. 2020;10(1):26–39.
   PubMed Web of Science ®Google Scholar
• Sokolowska O, Nowis D. STING signaling in cancer cells: important or not? Arch Immunol Ther Exp (Warsz). 2018;66(2):125–132.
   PubMed Web of Science ®Google Scholar
• Ho SSW, Zhang WYL, Tan NYJ, et al. The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity. 2016;44(5):1177–1189.
   PubMed Web of Science ®Google Scholar
• Shen YJ, Le Bert N, Chitre AA, et al. Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. Cell Rep. 2015;11(3):460–473.
   PubMed Web of Science ®Google Scholar
• Mackenzie KJ, Carroll P, Martin CA, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548(7668):461–465.
   PubMed Web of Science ®Google Scholar
• Xia T, Konno H, Ahn J, et al. Deregulation of STING signaling in colorectal carcinoma constrains DNA-damage responses and correlates with tumorigenesis. Cytokine. 2016;87(65):282–297.
   Google Scholar
• Kitajima S, Ivanova E, Guo S, et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 2019;9(1):34–45.
   PubMed Web of Science ®Google Scholar
• Xia T, Konno H, Ahn J, et al. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 2016;14(2):282–297.
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Kuhn L, Ellwanger S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35(8):615–620.
   PubMed Web of Science ®Google Scholar
• Ahn J, Ruiz P, Barber GN. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J Immunol. 2014;193(9):4634–4642.
   PubMed Web of Science ®Google Scholar
• Falahat R, Perez-Villarroel P, Mailloux AW, et al. STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity. Cancer Immunol Res. 2019;7(11):1837–1848.
   PubMed Web of Science ®Google Scholar
• An X, Zhu Y, Zheng T, et al. An analysis of the expression and association with immune cell infiltration of the cGAS/STING pathway in pan-cancer. Mol Ther Nucleic Acids. 2019;14:80–89.
   PubMedGoogle Scholar
• Hu QY, Knight PH, Ren YH, et al. The emerging role of stimulator of interferons genes signaling in sepsis: inflammation, autophagy, and cell death. Acta Physiol (Oxf). 2019;225(3):e13194.
   PubMed Web of Science ®Google Scholar
• Gao DX, Li T, Li XD, et al. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci U S A. 2015;112(42):E5699–E5705.
   PubMed Web of Science ®Google Scholar
• Ahn J, Gutman D, Saijo S, et al. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A. 2012;109(47):19386–19391.
   PubMed Web of Science ®Google Scholar
• Thim-Uam A, Prabakaran T, Tansakul M, et al. STING mediates lupus via the activation of conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation. iScience. 2020;23(9):101530.
   PubMed Web of Science ®Google Scholar
• Pastukh VM, Zhang L, Ruchko MV, et al. Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences. Int J Chronic Obstr. 2011;6:209–217.
   PubMed Web of Science ®Google Scholar
• Paschalaki KE, Starke RD, Hu YH, et al. Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem Cells. 2013;31(12):2813–2826.
   PubMed Web of Science ®Google Scholar
• Nascimento M, Gombault A, Lacerda-Queiroz N, et al. Self-DNA release and STING-dependent sensing drives inflammation to cigarette smoke in mice. Sci Rep. 2019;9(1):14848.
   PubMedGoogle Scholar
• Schuliga M, Read J, Blokland KEC, et al. Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clin Sci. 2020;134(7):889–905.
   Web of Science ®Google Scholar
• Han YL, Chen L, Liu HW, et al. Airway epithelial cGAS is critical for induction of experimental allergic airway inflammation. J Immunol. 2020;204(6):1437–1447.
   PubMed Web of Science ®Google Scholar
• Li N, Zhou H, Wu H, et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019;24:101215.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zeng L, Xie M, et al. TMEM173 drives lethal coagulation in sepsis. Cell Host Microbe. 2020;27(4):556–570.e6.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wei Y, Pandol SJ, et al. STING signaling promotes inflammation in experimental acute pancreatitis. Gastroenterology. 2018;154(6):1822–1835.e2.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Manohar M, Wei Y, et al. STING signalling protects against chronic pancreatitis by modulating Th17 response. Gut. 2019;68(10):1827–1837.
   PubMed Web of Science ®Google Scholar
• Hu Q, Wu J, Ren Y, et al. Degree of STING activation is associated with disease outcomes. Gut. 2020;69(4):792–794.
   PubMed Web of Science ®Google Scholar
• Martin GR, Blomquist CM, Henare KL, et al. Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice. Sci Rep. 2019;9(1):14281.
   PubMedGoogle Scholar
• Canesso MCC, Lemos L, Neves TC, et al. The cytosolic sensor STING is required for intestinal homeostasis and control of inflammation. Mucosal Immunol. 2018;11(3):820–834.
   PubMed Web of Science ®Google Scholar
• Yu YB, Yang WJ, Bilotta AJ, et al. STING controls intestinal homeostasis through promoting antimicrobial peptide expression in epithelial cells. FASEB J. 2020;34(11):15417–15430.
   PubMed Web of Science ®Google Scholar
• Larkin B, Ilyukha V, Sorokin M, et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J Immunol. 2017;199(2):397–402.
   PubMed Web of Science ®Google Scholar
• Gulen MF, Koch U, Haag SM, et al. Signalling strength determines proapoptotic functions of STING. Nat Commun. 2017;8(1):427.
   PubMedGoogle Scholar
• Brault M, Olsen TM, Martinez J, et al. Intracellular nucleic acid sensing triggers necroptosis through synergistic type I IFN and TNF signaling. J Immunol. 2018;200(8):2748–2756.
   PubMed Web of Science ®Google Scholar
• Petrasek J, Iracheta-Vellve A, Csak T, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci U S A. 2013;110(41):16544–16549.
   PubMed Web of Science ®Google Scholar
• Qiao JT, Cui C, Qing L, et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism. 2018;81:13–24.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–1274.
   PubMed Web of Science ®Google Scholar
• Lemos H, Huang L, McGaha TL, et al. Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol. 2014;44(10):2847–2853.
   PubMed Web of Science ®Google Scholar
• Qian S, Zhang M, Chen QL, et al. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery (vol 6, pg 7575, 2016). RSC Adv. 2016;6(66):61267–61267.
   Web of Science ®Google Scholar
• Lemos H, Mohamed E, Huang L, et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 2016;76(8):2076–2081.
   PubMed Web of Science ®Google Scholar
• Bakhoum SF, Ngo B, Laughney AM, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467–472.
   PubMed Web of Science ®Google Scholar
• Chen Q, Boire A, Jin X, et al. Corrigendum: carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2017;544(7648):124.
   PubMed Web of Science ®Google Scholar
• Zhong B, Yang Y, Li S, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity. 2008;29(4):538–550.
   PubMed Web of Science ®Google Scholar
• Li A, Yi M, Qin S, et al. Activating cGAS–STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019;12(1):35.
   PubMedGoogle Scholar
• Zhang X, Shi HP, Wu JX, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013;51(2):226–235.
   PubMed Web of Science ®Google Scholar
• Motedayen Aval L, Pease JE, Sharma R, et al. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020;9(10):3323.
   PubMed Web of Science ®Google Scholar
• Crosby EJ, Wei JPP, Yang XY, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7(5):e1421891.
   PubMed Web of Science ®Google Scholar
• Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol. 2019;11:1758835919830826.
   Web of Science ®Google Scholar
• Meric-Bernstam F, Sandhu SK, Hamid O, et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J Clin Oncol. 2019;37:2507.
   Google Scholar
• Le Naour J, Zitvogel L, Galluzzi L, et al. Trial watch: STING agonists in cancer therapy. Oncoimmunology. 2020;9(1):1777624.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, William WN, Khilnani A, et al. Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma. Ann Oncol. 2020;31:S683.
   Web of Science ®Google Scholar
• Challa S, Suppiah L, Cleary D, et al. Nanoparticle formulation of the STING agonist SB 11285. Cancer Immunol Res. 2020;8(3):123–123.
   Web of Science ®Google Scholar
• Plowman J, Narayanan VL, Dykes D, et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep. 1986;70(5):631–635.
   PubMedGoogle Scholar
• Shih AY, Damm-Ganamet KL, Mirzadegan T. Dynamic structural differences between human and mouse STING lead to differing sensitivity to DMXAA. Biophys J. 2018;114(1):32–39.
   PubMed Web of Science ®Google Scholar
• Conlon J, Burdette DL, Sharma S, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol. 2013;190(10):5216–5225.
   PubMed Web of Science ®Google Scholar
• Lara P, Douillard J, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(22):2965–2971.
   PubMed Web of Science ®Google Scholar
• Jang SC, Moniz RJ, Sia CL, et al. exoSTING: an engineered exosome therapeutic that selectively delivers STING agonist to the tumor resident antigen-presenting cells resulting in improved tumor antigen-specific adaptive immune response. Cancer Res. 2019;79:13–944.
   Web of Science ®Google Scholar
• Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564(7736):439–443.
   PubMed Web of Science ®Google Scholar
• Lorkowski ME, Atukorale PU, Bielecki PA, et al. Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. J Control Release. 2020.
   Google Scholar
• Cui X, Zhang R, Cen S, et al. STING modulators: predictive significance in drug discovery. Eur J Med Chem. 2019;182:111591.
   PubMed Web of Science ®Google Scholar
• Shae D, Becker KW, Christov P, et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14(3):269–278.
   PubMed Web of Science ®Google Scholar
• Wang-Bishop L, Wehbe M, Shae D, et al. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma. J Immunother Cancer. 2020;8(1):e000282.
   PubMed Web of Science ®Google Scholar
• Demaria O, Gestermann N, Di DJ, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. J Invest Dermatol. 2015;135:S21.
   Web of Science ®Google Scholar
• Baird JR, Friedman D, Cottam B, et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 2016;76(1):50–61.
   PubMed Web of Science ®Google Scholar
• Sallets A, Robinson S, Kardosh A, et al. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Adv. 2018;2(17):2230–2241.
   PubMed Web of Science ®Google Scholar
• Yang H, Lee WS, Kong SJ, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019;129(10):4350–4364.
   PubMed Web of Science ®Google Scholar
• Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014;35(2):88–93.
   PubMed Web of Science ®Google Scholar
• Schoggins JW, MacDuff DA, Imanaka N, et al. Corrigendum: pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 2015;525(7567):144–144.
   Web of Science ®Google Scholar
• Ma Z, Jacobs SR, West JA, et al. Modulation of the cGAS–STING DNA sensing pathway by gammaherpesviruses. Proc Natl Acad Sci U S A. 2015;112(31):E4306–E4315.
   PubMed Web of Science ®Google Scholar
• Hernaez B, Alonso G, Georgana I, et al. Viral cGAMP nuclease reveals the essential role of DNA sensing in protection against acute lethal virus infection. Sci Adv. 2020;6(38):eabb4565.
   PubMed Web of Science ®Google Scholar
• Wilski NA, Stotesbury C, Del Casale C, et al. STING sensing of murine cytomegalovirus alters the tumor microenvironment to promote antitumor immunity. J Immunol. 2020;204(11):2961–2972.
   PubMed Web of Science ®Google Scholar
• Guo F, Han Y, Zhao X, et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother. 2015;59(2):1273–1281.
   PubMed Web of Science ®Google Scholar
• Gall B, Pryke K, Abraham J, et al. Emerging alphaviruses are sensitive to cellular states induced by a novel small-molecule agonist of the STING pathway. J Virol. 2017;92(6):e01913–e01917.
   Web of Science ®Google Scholar
• Yi M, Qin S, Zhao WH, et al. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol. 2018;7:28.
   PubMed Web of Science ®Google Scholar
• Zheng D, Gao FX, Zhao C, et al. Comparative effectiveness of H7N9 vaccines in healthy individuals. Hum Vaccin Immunother. 2019;15(1):80–90.
   PubMed Web of Science ®Google Scholar
• Luo J, Liu XP, Xiong FF, et al. Enhancing immune response and heterosubtypic protection ability of inactivated H7N9 vaccine by using STING agonist as a mucosal adjuvant. Front Immunol. 2019;10:2274.
   PubMed Web of Science ®Google Scholar
• Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435–443.
   PubMed Web of Science ®Google Scholar
• Vassilieva EV, Taylor DW, Compans RW. Combination of STING pathway agonist with saponin is an effective adjuvant in immunosenescent mice. Front Immunol. 2019;10:3006.
   PubMed Web of Science ®Google Scholar
• Sivick KE, Desbien AL, Glickman LH, et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 2018;25(11):3074–3085.
   PubMed Web of Science ®Google Scholar